Metraipolis › archive › dc_b5f79cbb24ae

Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis — Europe PMC PMID:41163639

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41163639
DOI
10.7759/cureus.95519
License (as archived)
solo-consultazione
Archived
2026-11-09T00:58:20.704Z
SHA-256 of the archived text
f30fc65626648567e9dc6e1f23427c03e83a3ef76a880945ab50106bdfdff6b7
Stable URL of this page
https://metraipolis.com/documento/dc_b5f79cbb24ae

How to cite

Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis — Europe PMC PMID:41163639 — Europe PMC (en), https://europepmc.org/article/MED/41163639 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b5f79cbb24ae (Metraipolis archive dc_b5f79cbb24ae, sha256 f30fc65626648567e9dc6e1f23427c03e83a3ef76a880945ab50106bdfdff6b7)
BibTeX
@misc{dcb5f79cbb24ae,
  title = {Lactulose Versus Rifaximin Monotherapy for Hepatic Encephalopathy Prevention: A Prospective Comparative Study in Patients With Cirrhosis — Europe PMC PMID:41163639},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41163639},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b5f79cbb24ae; sha256 f30fc65626648567e9dc6e1f23427c03e83a3ef76a880945ab50106bdfdff6b7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41163639. Agents can read the archived copy with the MCP tool read_document.